Skip to main content
OpenTrials
Completed

NCT Number: NCT04217200

Pregnancy Dating Test - The Fall of hPL in Urine Over Time

Earlier studies describe the half-life of hPL in serum as being ninety minutes and that the hormone is excreted unchanged in urine; consequently, there is real potential to use the fall in hormone levels in urine to monitor bleeding in pregnancy, the outcome of natural and artificial abortions or placental health.

This study will focus on the fall of hPL following delivery by Caesarean section when women have a urinary catheter in place and sampling urine is simple to achieve.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–52 year

Sex eligibility

Female

Study type

Observational

Primary location

Guy's & St Thomas' NHS Foundation Trust

London, England, SE1 7AB, United Kingdom

About this study

The hormone hPL has a 90 minute half life in serum and the consequently since it is excreted unchanged in the urine it could be a useful marker to evaluate bleeding in pregnancy, determine if a pregnancy has ended by natural and artificial abortion or if there has been a change in placental function during a normal pregnancy.

The project will recruit twelve pregnant women having an elective Caesarean section to determine the fall in hPL over time. Urine samples will be taken just prior to and then every 30 minutes for the first six hours after delivery by Caesarean section.

Pregnant women presenting for an elective Caesarean section at Guy's & St Thomas' NHS Foundation Trust (GSTFT) will be approached to join this study and the following will be done:

  • Invited to participate in study and given Patient Information Leaflet
  • Informed consent obtained
  • Eligibility for inclusion determined
  • A urine sample (20ml) will be collected prior to the Caesarean from the urinary catheter
  • Then urine samples (20mls) will be collected every 30 minutes for the first six hours following Caesarean section delivery
  • The result of the dating ultrasound scan will be added to the trial documentation record
  • The weight of the baby will be added to the trial documentation record

Consent The patient information leaflet clearly states the purpose of the research and the low risk of participation. The co-signing researcher on the consent form will ensure that the signee understands the alternative, is able to retain the relevant information, has capacity and is exercising free choice.

Risks, burdens and benefits This trial involves the collection of serial urine samples. The clinical history and result of the dating ultrasound scan will be recorded to estimate the gestation at delivery. The analysis of these samples will have no bearing on their clinical care.

Confidentiality All women recruited to the trial will be given a unique trial number. The trial data sheet will have the following information. The trial site, unique trial number, date of birth, date, estimated gestation from the result from the dating ultrasound scan. The samples collected will have the following information recorded: the unique trial number, date of birth, date and trial site code.

Conflict of interest None has been identified.

Use of tissue samples in future research The samples will not be stored.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The women is 18 years of age or older
  • She understands the patient information leaflet, trial requirements and has signed the consent form
  • The Caesarean delivery will be at GSTFT
  • Prepared for urine to be collected for up to when the urinary catheter is removed or six hours, whichever is sooner
  • Agrees for the demographic and medical history data to be collected.

Exclusion criteria

  • Under 18 years of age
  • Unable to understand the patient information leaflet or consent to join the trial
  • The Caesarean delivery will not be at GSTFT
  • The women is not for urine to be collected
  • The women does not agree for demographic or history data to be collected.
  • The women has a haemorrhage greater than one litre during the Caesarean delivery

Treatment and study plan

Primary outcomes

  1. The rate of change in human placental lactogen concentration in urine post delivery by Caesarian section

    Time frame: Baseline and then 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 & 360 minutes after delivery of the baby by Caesarean section

Sponsors and collaborators

Lead sponsor

Guy's and St Thomas' NHS Foundation Trust

Other

Collaborators

  • King's College Hospital NHS Trust

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jan 3, 2020
Registry last updated
Jun 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.